No code, no problem ...
Eli Lilly is heading back to its regular Chinese collaborator Innovent Biologics with $350 million in upfront cash to collaborate on new meds for patients with cancer or immune disorders. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results